EGFR and non-small cell lung carcinoma: Moreover, even though their response rate is lower than with mutant EGFR‐expressing patients, 20–30% of NSCLC patients with amplified wtEGFR can still derive significant survival benefit from an EGFR TKI regimen (Bell et al., 2005; Cappuzzo et al., 2005; Tsao et al., 2005).